Teva Pharmaceutical Industries Limited
NYSE:TEVADrug Manufacturers - Specialty & Generic
-$1.09 today
- Market cap
- $49.28B
- Beta
- 0.85
- P/E (TTM)
- 23.1
- EPS (TTM)
- $1.36
Volume 8.86M
Average 6.22M
TEVA Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Teva Pharmaceutical Industries LimitedNYSE: TEVA
Net Income · Q2 FY2026 · quarter ended Jun 2026
Net income turns negative
Q2 FY2026 net income was -$575M, compared with $283M a year earlier. Trailing-twelve-month net income was $709M.
Context
- Net income amounted to 8.2% of revenue in FY2025, down 3.6 pp from a year earlier.
- Net income increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 9 analysts of $2.42B (+70.3%) for the fiscal year ending Dec 2026, a slowdown from the +172.4% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- -$575M-255.8% QoQ
- Last fiscal yearDec 2025
- $1.42B+172.4% YoY
- LTMJun 2026
- $709M+537.7% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -303.2% | +96.5% | +399.7 pp |
| 1 year | +172.4% | +70.3% | -102.1 pp |
| 3-year CAGR | — | +44.3% | — |
| 5-year CAGR | +27.8% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- 1.42B USD
- Year-over-year change
- +172.4%
- 4-year CAGR
- +32.8%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.42B | +172.4% |
| FY2024 | 2024-12-31 | (1.96B) | -218.5% |
| FY2023 | 2023-12-31 | (615M) | +75.4% |
| FY2022 | 2022-12-31 | (2.5B) | -648.0% |
| FY2021 | 2021-12-31 | 456M | — |
Net Income vs competitors
How TEVA compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +537.7% is the highest of 5, against a peer median of -70.3%.
- Net income amounts to 4.1% of revenue for TEVA, versus a peer median of 7.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | ₹27.72B INR | -52.4% | +0.0% | 8.4% | |
| LTM Jun 2026 | $709M USD | +537.7% | — | 4.1% | |
| LTM Jun 2026 | $410.7M USD | -88.2% | — | 2.8% | |
| LTM Jun 2026 | $215.32M USD | +320.2% | — | 6.9% | |
| LTM Mar 2026 | $80.73M USD | -183.6% | — | 14.4% | |
| Peer median (excluding TEVA) | — | -70.3% | +0.0% | 7.6% | |
Competitors are the stored peer set for TEVA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 456M | (2.5B) | (615M) | (1.96B) | 1.42B |
| Depreciation & Amortization | 1.33B | 1.31B | 1.15B | 1.06B | 1B |
| Deferred Income Tax | (120M) | (1.06B) | (317M) | (634M) | (671M) |
| Stock-Based Compensation | 119M | 124M | 121M | 123M | 157M |
| Change in Working Capital | (1.7B) | 1.36B | (72M) | (435M) | (1.37B) |
| Accounts Receivables | (574M) | 334M | 12M | 245M | (173M) |
| Inventory | 380M | (163M) | (147M) | 166M | 152M |
| Accounts Payables | 764M | 2.01B | 1.59B | 258M | (15M) |
| Other Working Capital | (2.27B) | (828M) | (1.53B) | (1.1B) | (1.33B) |
| Other Non-Cash Items | 714M | 2.37B | 1.1B | 3.09B | 1.11B |
| Operating Cash Flow | 798M | 1.59B | 1.37B | 1.25B | 1.65B |
| Capital Expenditures | (562M) | (548M) | (526M) | (498M) | (501M) |
| Acquisitions (Net) | 1.96B | 61M | 68M | 28M | 34M |
| Purchases of Investments | (47M) | (1M) | (46M) | (71M) | (57M) |
| Sales of Investments | 172M | 4M | 0 | 40M | 42M |
| Other Investing Activities | 1M | 1.14B | 1.47B | 1.29B | 1.22B |
| Investing Cash Flow | 1.52B | 656M | 968M | 792M | 737M |
| Debt Repayment | (2.17B) | (1.37B) | (1.7B) | (1.64B) | (1.81B) |
| Common Stock Issued | 0 | 0 | 0 | 0 | 0 |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (6M) | (118M) | (212M) | (150M) | (337M) |
| Financing Cash Flow | (2.17B) | (1.49B) | (1.91B) | (1.79B) | (2.15B) |
| Effect of Forex Changes | (128M) | (123M) | (30M) | (175M) | 21M |
| Net Change in Cash | 21M | 636M | 393M | 73M | 256M |
| Free Cash Flow | 236M | 1.04B | 842M | 749M | 1.15B |
Teva Pharmaceutical Industries Limited
NYSE:TEVA
Intrinsic Alpha fair value
Locked
Current Price
$42.23
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.